RNAi技术市场－全球产业规模、份额、趋势、机会、预测：按类型、应用、最终用户、地区和竞争格局划分，2021-2031年

全球 RNAi 技术市场预计将从 2025 年的 16.1 亿美元成长到 2031 年的 29.9 亿美元，复合年增长率达到 10.87%。

该领域涵盖了透过RNA干扰机制中和特定mRNA分子并抑制基因表现来治疗遗传性疾病、病毒感染疾病和恶性肿瘤的研究工具和疗法。市场成长的主要驱动力是慢性病发病率的上升以及对精准医疗（能够治疗以往无法治癒的疾病）的迫切需求。此外，药物递送系统（尤其是脂质奈米颗粒製剂）的不断进步，正在提高这些疗法的稳定性和生物利用度，从而促进其在临床实践中的更广泛应用。

儘管取得了这些进展，但将RNA分子递送至肝臟以外的组织仍然十分复杂，这仍然是限制这些技术目前治疗范围的主要障碍。开发能够确保RNA分子在血液中稳定性并促进细胞内吸收且不引发脱靶免疫反应的解决方案，持续增加研发的难度。然而，正如美国基因与细胞治疗学会（ASGCT）的数据所示，业界仍在努力克服这些转化挑战。 2025年第二季度，启动了38项新的临床试验，显着扩展了RNA疗法的研发管线。这表明业界仍在持续投入，以应对这些挑战。

市场驱动因素

癌症和慢性感染疾病率的上升是全球RNAi技术市场成长的主要驱动力。传统治疗方法往往难以应对复杂的遗传因素，而RNA干扰技术提供了一种独特的机制，能够高精度地沉默特定的疾病相关基因。日益加重的疾病负担凸显了这项迫切需求。美国癌症协会发布的《2025年癌症事实与数据》报告预测，2025年，美国将新增超过200万例癌症病例。因此，RNAi疗法能够针对以往「无法治疗」的靶点，这使其成为未来肿瘤和感染疾病治疗方法中不可或缺的一部分。

同时，生命科学领域的策略合作和授权协议正透过提供推动临床研发所需的资金来加速市场扩张。领先的製药公司正越来越多地与专业的生物技术公司合作，以利用其专有平台并降低研发风险。例如，正如GeneOnline在2025年9月报导的那样，诺华公司向其与Argo Biopharma的合作追加投资52亿美元，以推进用于治疗心血管疾病的RNAi疗法的研发。这些合作有效地将研发与商业性成果联繫起来，作为这项进展的佐证，Arrowhead Pharmaceuticals在2025年宣布，其用于治疗遗传性乳糜微粒血症症候群的新型RNAi疗法prozasilan已获得美国FDA核准。

市场挑战

将RNA分子高效率地递送至肝臟以外的其他组织是限制全球RNAi技术市场扩张的主要障碍。儘管现有技术在靶向肝臟方面已取得成功，但如何开发能够到达大脑、心臟和肺部等器官且不引起降解或毒性的递送方法，严重限制了市场发展。这项技术限制使得RNAi疗法的商业性应用范围仅限于少数适应症，从而有效地限制了目标市场，并阻碍了其进入神经病学和广谱肿瘤学等高需求治疗领域。

因此，确保药物在血液中的稳定性并防止脱靶免疫反应的复杂性，给药物研发过程带来了巨大的阻力。这些转化障碍增加了新药候选者的风险，导致研发週期延长，临床试验也需要更加谨慎。这些障碍的影响在近期的产业指标中显而易见。根据美国基因与细胞治疗学会（ASGCT）的数据，2025年第三季基因、细胞和RNA疗法的临床研发活动整体放缓，新启动的临床实验数量在经历了上一季的大幅增长后，降至125项。这项萎缩凸显了与递送技术相关的难题如何直接阻碍了研发管线的进展，并延缓了市场成熟。

市场趋势

基于RNAi的生物农药和农业解决方案的商业化，正从根本上拓展市场，使其不再局限于人类治疗领域，而是应用于作物保护的关键挑战。这一趋势利用RNA干扰的特异性，在不损害永续或环境的前提下，沉默害虫体内的关键基因，从而为传统的化学药剂提供了一种可持续的替代方案。产业相关人员正在加速资金筹措，以推动这些环境友善平台从实验室走向田间试验。例如，Renaissance BioScience公司于2025年9月宣布，已获得加拿大政府83万加元的资金筹措，用于加速其专有的RNAi生物防治技术在农业领域的应用开发。

同时，支持RNAi疗法大规模生产的结构性变革之一是对合约研发生产机构（CDMO）在可扩展寡核苷酸生产方面的依赖性日益增强。随着研发管线扩展到高频疾病领域，研发公司正将生产外包给拥有先进製造能力和商业规模所需监管专业知识的专业机构。这种策略性外包使製药公司能够降低技术製造风险，并加快为大规模的患者群体建立供应链。为了支持这项扩张，Bachem在2025年7月报告称，该公司在上半年投资了1.291亿瑞士法郎，重点用于扩大其全球生产网路的产能。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球RNAi技术市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（微型RNA、小干扰RNA、其他）
  • 依应用领域（治疗类型、治疗药物、药物传递、农业、其他）
  • 按最终用户（研究和学术机构、诊断实验室等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美RNAi技术市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲RNAi技术市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区RNAi技术市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲RNAi技术市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美RNAi技术市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球RNAi技术市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Alnylam Pharmaceuticals, Inc
• Ionis Pharmaceuticals, Inc.
• Atalanta Therapeutics Inc.
• Phio Pharmaceuticals Corp.
• Benitec Biopharma Ltd.
• Novartis AG
• AstraZeneca PLC
• Silence Therapeutics Plc.
• Arbutus Biopharma Corp.
• Sylentis SA

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global RNAi Technology Market is projected to expand from USD 1.61 Billion in 2025 to USD 2.99 Billion by 2031, achieving a compound annual growth rate of 10.87%. This sector encompasses both research tools and therapeutics that employ RNA interference mechanisms to neutralize specific mRNA molecules, thereby inhibiting gene expression to address genetic disorders, viral infections, and malignancies. The market's growth is primarily driven by the increasing incidence of chronic diseases and the surging demand for precision medicine capable of treating targets that were previously considered undruggable. Furthermore, continuous advancements in drug delivery systems, particularly lipid nanoparticle formulations, are improving the stability and bioavailability of these therapeutics, which facilitates their broader clinical adoption.

Despite these advances, the complexity of delivering RNA molecules to tissues outside the liver presents a significant obstacle that limits the current therapeutic reach of these technologies. Developing solutions that ensure stability within the bloodstream and facilitate cellular uptake without provoking off-target immune reactions continues to complicate development timelines. However, the industry remains committed to overcoming these translational hurdles, as evidenced by data from the American Society of Gene & Cell Therapy; in the second quarter of 2025, the RNA therapy pipeline grew significantly with the initiation of 38 new clinical trials, signaling persistent investment in addressing these challenges.

Market Driver

The escalating prevalence of cancer and chronic infectious diseases acts as a primary engine for growth in the Global RNAi Technology Market. Because conventional therapeutic modalities frequently struggle to address complex genetic drivers, RNA interference offers a unique mechanism for silencing specific disease-causing genes with high precision. This critical need is highlighted by the rising disease burden; the American Cancer Society's "Cancer Facts & Figures 2025" report projected that more than 2 million new cancer cases would be diagnosed in the United States in 2025. Consequently, the ability of RNAi therapeutics to engage targets previously deemed undruggable positions them as essential components of future treatment regimens for oncology and infectious diseases.

Simultaneously, strategic collaborations and licensing agreements within the life sciences sector are accelerating market expansion by providing the necessary capital to advance clinical pipelines. Leading pharmaceutical companies are increasingly partnering with specialized biotech firms to utilize proprietary platforms and mitigate development risks. For example, GeneOnline reported in September 2025 that Novartis committed an additional $5.2 billion to its collaboration with Argo Biopharma to develop RNAi therapies for cardiovascular conditions. These alliances are effectively translating research and development into commercial reality; underscoring this progress, Arrowhead Pharmaceuticals announced in 2025 that the U.S. FDA approved plozasiran, a novel RNAi therapeutic for familial chylomicronemia syndrome.

Market Challenge

The difficulty of efficiently delivering RNA molecules to tissues beyond the liver constitutes a formidable barrier that hampers the expansion of the Global RNAi Technology Market. Although current technologies have proven successful for hepatic targets, the market is severely constrained by the challenge of engineering delivery vehicles capable of navigating to organs such as the brain, heart, or lungs without degrading or causing toxicity. This technical limitation confines the commercial scope of RNAi therapeutics to a narrow range of indications, effectively capping the addressable market and preventing entry into high-demand therapeutic areas like neurology and broad-spectrum oncology.

Consequently, the complexity of ensuring bloodstream stability and preventing off-target immune responses has introduced significant friction into the drug development process. These translational obstacles increase the risk profile of new candidates, leading to extended development timelines and a more cautious approach to clinical progression. The impact of these barriers is evident in recent industry metrics; according to the American Society of Gene & Cell Therapy, clinical development activity slowed across the broader gene, cell, and RNA landscape in the third quarter of 2025, with total trial initiations falling to 125 after a surge in the previous quarter. This contraction highlights how delivery-related difficulties directly throttle the pipeline's velocity and delay market maturation.

Market Trends

The commercialization of RNAi-based biopesticides and agricultural solutions is fundamentally diversifying the market beyond human therapeutics by addressing critical challenges in crop protection. This trend utilizes the specificity of RNA interference to silence essential genes in pests without harming beneficial insects or the environment, offering a sustainable alternative to conventional chemical agents. Industry players are increasingly securing capital to advance these eco-friendly platforms from the laboratory to field trials; for instance, Renaissance BioScience announced in September 2025 that it secured CAN$830,000 in funding from the Government of Canada to accelerate the development of its proprietary RNAi biocontrol technology for the agriculture sector.

Concurrently, an increasing reliance on Contract Development and Manufacturing Organizations (CDMOs) for scalable oligonucleotide manufacturing is emerging as a structural shift to support the mass production of RNAi therapeutics. As the pipeline expands into high-prevalence indications, developers are externalizing production to specialized organizations that offer the advanced capacity and regulatory expertise required for commercial volumes. This strategic outsourcing allows pharmaceutical firms to mitigate technical manufacturing risks and accelerate supply chain readiness for large-scale patient populations. Underscoring this expansion, Bachem reported in July 2025 that it invested CHF 129.1 million in the first half of the year specifically to expand production capacity across its global site network.

Key Market Players

• Alnylam Pharmaceuticals, Inc
• Ionis Pharmaceuticals, Inc.
• Atalanta Therapeutics Inc.
• Phio Pharmaceuticals Corp.
• Benitec Biopharma Ltd.
• Novartis AG
• AstraZeneca PLC
• Silence Therapeutics Plc.
• Arbutus Biopharma Corp.
• Sylentis S.A.

Report Scope

In this report, the Global RNAi Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNAi Technology Market, By Type

• Micro RNA
• Small interfering RNA
• Others

RNAi Technology Market, By Application

• Treatment Type
• Therapeutics
• Drug Delivery
• Agriculture
• Others

RNAi Technology Market, By End User

• Research and Academic Laboratories
• Diagnostic Laboratories
• Others

RNAi Technology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNAi Technology Market.

Available Customizations:

Global RNAi Technology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global RNAi Technology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Micro RNA, Small interfering RNA, Others)
  • 5.2.2. By Application (Treatment Type, Therapeutics, Drug Delivery, Agriculture, Others)
  • 5.2.3. By End User (Research and Academic Laboratories, Diagnostic Laboratories, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America RNAi Technology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States RNAi Technology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada RNAi Technology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico RNAi Technology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe RNAi Technology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany RNAi Technology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France RNAi Technology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom RNAi Technology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy RNAi Technology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain RNAi Technology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific RNAi Technology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China RNAi Technology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India RNAi Technology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan RNAi Technology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea RNAi Technology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia RNAi Technology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa RNAi Technology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia RNAi Technology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE RNAi Technology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa RNAi Technology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America RNAi Technology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil RNAi Technology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia RNAi Technology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina RNAi Technology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global RNAi Technology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Alnylam Pharmaceuticals, Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Ionis Pharmaceuticals, Inc.
• 15.3. Atalanta Therapeutics Inc.
• 15.4. Phio Pharmaceuticals Corp.
• 15.5. Benitec Biopharma Ltd.
• 15.6. Novartis AG
• 15.7. AstraZeneca PLC
• 15.8. Silence Therapeutics Plc.
• 15.9. Arbutus Biopharma Corp.
• 15.10. Sylentis S.A.

16. Strategic Recommendations

17. About Us & Disclaimer